|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006610,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0085533,
umls-concept:C0205179,
umls-concept:C0205197,
umls-concept:C0205225,
umls-concept:C0229671,
umls-concept:C0441889,
umls-concept:C0677886,
umls-concept:C1511572,
umls-concept:C1514474,
umls-concept:C2347296
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-6-12
|
|
pubmed:abstractText |
The aim of this study was to evaluate the prognostic value of the serum CA-125 level for complete responders after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy in advanced epithelial ovarian cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1423-0240
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2008 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
315-20
|
|
pubmed:meshHeading |
pubmed-meshheading:18547972-Adult,
pubmed-meshheading:18547972-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18547972-CA-125 Antigen,
pubmed-meshheading:18547972-Carboplatin,
pubmed-meshheading:18547972-Carcinoma,
pubmed-meshheading:18547972-Chemotherapy, Adjuvant,
pubmed-meshheading:18547972-Female,
pubmed-meshheading:18547972-Humans,
pubmed-meshheading:18547972-Incidence,
pubmed-meshheading:18547972-Korea,
pubmed-meshheading:18547972-Male,
pubmed-meshheading:18547972-Middle Aged,
pubmed-meshheading:18547972-Neoplasm Proteins,
pubmed-meshheading:18547972-Neoplasm Staging,
pubmed-meshheading:18547972-Ovarian Neoplasms,
pubmed-meshheading:18547972-Paclitaxel,
pubmed-meshheading:18547972-Prognosis,
pubmed-meshheading:18547972-Reproducibility of Results,
pubmed-meshheading:18547972-Sensitivity and Specificity,
pubmed-meshheading:18547972-Survival Analysis,
pubmed-meshheading:18547972-Survival Rate,
pubmed-meshheading:18547972-Treatment Outcome,
pubmed-meshheading:18547972-Tumor Markers, Biological
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article
|
